Tandem Diabetes Care (TNDM) Debt to Equity (2013 - 2025)

Tandem Diabetes Care (TNDM) reported Debt to Equity of $0.26 for Q1 2025, up 69.7% quarter-over-quarter from $0.15 in Q4 2024.

Tandem Diabetes Care (TNDM) Debt to Equity (2013 - 2025) Analysis & Trends

Tandem Diabetes Care has reported Debt to Equity for 8 years, with the latest figure at $0.26 in Q1 2025.

For the quarter ending Q1 2025, Debt to Equity changed N/A year-over-year to $0.26; the trailing twelve-month figure through Mar 2025 stood at $0.26 (changed N/A YoY), and the FY2024 full-year result was $0.15, changed N/A from the prior year.
Debt to Equity for Q1 2025 stood at $0.26, up from $0.15 in the prior quarter.
The five-year high for Debt to Equity was $0.26 in Q1 2025, with the low at $0.15 in Q4 2024.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	0.65
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	0.64
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	0.57
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	0.42
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	0.06
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	0.71
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	0.95
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	0.27
10	Tandem Diabetes Care	1.04 Bn	474.17 Mn	136.79 Mn	-

Historic Data

Download Data

Date	Value
Mar 31, 2025	0.26
Dec 31, 2024	0.15
Sep 30, 2024	0.17
Jun 30, 2024	0.17
Jun 30, 2018	2.96
Mar 31, 2018	6.45
Dec 31, 2017	-2.63
Sep 30, 2017	-2.70
Jun 30, 2017	-4.09
Mar 31, 2017	-39.49
Dec 31, 2016	-13.32
Sep 30, 2016	8.60
Jun 30, 2016	1.38
Mar 31, 2016	0.96
Dec 31, 2015	0.46
Sep 30, 2015	0.41
Jun 30, 2015	0.34
Mar 31, 2015	0.29
Dec 31, 2014	0.54
Dec 31, 2013	0.25